| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $1,612,867 ) |
| | 2024 | 2024 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R01HD101535 | Reductions in biopsychosocial risks for pregnant Latinas and their infants: the Mastery Lifestyle Intervention | 000 | 4 | NIH | 2/23/2024 | $558,494 |
| | 2024 | 2024 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R01HD101535 | Reductions in biopsychosocial risks for pregnant Latinas and their infants: the Mastery Lifestyle Intervention | 001 | 4 | NIH | 5/2/2024 | $55,850 |
| | 2024 | 2024 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R44DC019890 | Development of a High Throughput Assay for Rapid Screening of Congenital Cytomegalovirus Infection using Dried Blood Spots | 000 | 3 | NIH | 7/5/2024 | $998,523 |
| | 2024 | 2023 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43PS005273 | PA21259, SBIR, Phase I, Development of a High Throughput Assay for Rapid Detection of HSV and Treponema pallidum | 02 | 1 | CDC | 8/22/2024 | $0 |
| | 2024 | 2023 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43PS005273 | PA21259, SBIR, Phase I, Development of a High Throughput Assay for Rapid Detection of HSV and Treponema pallidum | 01 | 1 | CDC | 5/31/2024 | $0 |
| | 2024 | 2023 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43PS005273 | PA21259, SBIR, Phase I, Development of a High Throughput Assay for Rapid Detection of HSV and Treponema pallidum | 01 | 1 | CDC | 5/31/2024 | $0 |
| | 2024 | 2023 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43PS005273 | PA21259, SBIR, Phase I, Development of a High Throughput Assay for Rapid Detection of HSV and Treponema pallidum | 02 | 1 | CDC | 8/22/2024 | $0 |
| | 2024 | 2022 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R03AI151426 | The Impact of Maternal CMV Infection on Birth Outcomes | 000 | 2 | NIH | 7/22/2024 | $0 |
| | 2024 | 2022 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43DC019890 | Development of a High Throughput Assay for Rapid Screening of Congenital Cytomegalovirus Infection using Dried Blood Spots | 000 | 1 | NIH | 2/2/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,961,503 ) |
| | 2023 | 2023 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R01HD101535 | Reductions in biopsychosocial risks for pregnant Latinas and their infants: the Mastery Lifestyle Intervention | 000 | 3 | NIH | 2/24/2023 | $627,249 |
| | 2023 | 2023 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R44DC019890 | Development of a High Throughput Assay for Rapid Screening of Congenital Cytomegalovirus Infection using Dried Blood Spots | 000 | 2 | NIH | 6/30/2023 | $1,034,453 |
| | 2023 | 2023 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43PS005273 | PA21259, SBIR, Phase I, Development of a High Throughput Assay for Rapid Detection of HSV and Treponema pallidum | 00 | 1 | CDC | 8/30/2023 | $74,735 |
| | 2023 | 2023 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43PS005273 | PA21259, SBIR, Phase I, Development of a High Throughput Assay for Rapid Detection of HSV and Treponema pallidum | 00 | 1 | CDC | 8/30/2023 | $225,066 |
| | 2023 | 2020 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43AI152629 | Rapid User Friendly POC Diagnostic for HSV | 000 | 1 | NIH | 6/27/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,007,079 ) |
| | 2022 | 2022 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R01HD101535 | Reductions in biopsychosocial risks for pregnant Latinas and their infants: the Mastery Lifestyle Intervention | 001 | 2 | NIH | 4/30/2022 | $62,595 |
| | 2022 | 2022 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43DC019890 | Development of a High Throughput Assay for Rapid Screening of Congenital Cytomegalovirus Infection using Dried Blood Spots | 000 | 1 | NIH | 6/13/2022 | $291,613 |
| | 2022 | 2022 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R03AI151426 | The Impact of Maternal CMV Infection on Birth Outcomes | 000 | 2 | NIH | 12/15/2021 | $89,515 |
| | 2022 | 2022 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R01HD101535 | Reductions in biopsychosocial risks for pregnant Latinas and their infants: the Mastery Lifestyle Intervention | 000 | 2 | NIH | 2/25/2022 | $563,356 |
| | 2022 | 2019 | MICROGEN LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R03AI135154 | Cytometric Enumeration of EBV-Infected Cells | 000 | 2 | NIH | 12/13/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $732,908 ) |
| | 2021 | 2021 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R03AI151426 | The Impact of Maternal CMV Infection on Birth Outcomes | 000 | 1 | NIH | 1/21/2021 | $89,515 |
| | 2021 | 2021 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R01HD101535 | Reductions in biopsychosocial risks for pregnant Latinas and their infants: the Mastery Lifestyle Intervention | 000 | 1 | NIH | 4/7/2021 | $640,626 |
| | 2021 | 2021 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R01HD101535 | Reductions in biopsychosocial risks for pregnant Latinas and their infants: the Mastery Lifestyle Intervention | 001 | 1 | NIH | 5/28/2021 | $2,767 |
| | 2021 | 2019 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43AI134194 | Low Cost Point-Of-Care Test For CMV | 001 | 1 | NIH | 2/22/2021 | $0 |
| | 2021 | 2017 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43AI134194 | Low Cost Point-Of-Care Test For CMV | 000 | 1 | NIH | 1/14/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $189,631 ) |
| | 2020 | 2020 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43AI152629 | Rapid User Friendly POC Diagnostic for HSV | 000 | 1 | NIH | 5/11/2020 | $189,631 |
|
| Issue Date FY: 2019 ( Subtotal = $218,655 ) |
| | 2019 | 2019 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43AI134194 | Low Cost Point-Of-Care Test For CMV | 001 | 1 | NIH | 5/15/2019 | $122,205 |
| | 2019 | 2019 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R03AI135154 | Cytometric Enumeration of EBV-Infected Cells | 001 | 2 | NIH | 5/9/2019 | $87,475 |
| | 2019 | 2018 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R03AI135154 | Cytometric Enumeration of EBV-Infected Cells | 000 | 1 | NIH | 4/4/2019 | $8,975 |
| | 2019 | 2017 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43AI134194 | Low Cost Point-Of-Care Test For CMV | 000 | 1 | NIH | 5/15/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $78,500 ) |
| | 2018 | 2018 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R03AI135154 | Cytometric Enumeration of EBV-Infected Cells | 001 | 1 | NIH | 6/11/2018 | $0 |
| | 2018 | 2018 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R03AI135154 | Cytometric Enumeration of EBV-Infected Cells | 000 | 1 | NIH | 5/29/2018 | $78,500 |
|
| Issue Date FY: 2017 ( Subtotal = $223,447 ) |
| | 2017 | 2017 | MICROGEN, LLC | 903 TEXAS AVE | LA MARQUE | TX | 77568-3318 | GALVESTON | USA | R43AI134194 | Low Cost Point-Of-Care Test For CMV | 000 | 1 | NIH | 7/12/2017 | $223,447 |
|
| Issue Date FY: 2011 ( Subtotal = $76,725 ) |
| | 2011 | 2011 | MICROGEN LLC | 101 CHRISTOPHER COLUMBUS BLVD | GALVESTON | TX | 77550 | GALVESTON | USA | R03AI083062 | 3-D ORAL MUCOSA MODEL FOR EBV PATHOGENESIS | 000 | 2 | NIH | 6/16/2011 | $76,725 |
|
| Issue Date FY: 2010 ( Subtotal = $154,225 ) |
| | 2010 | 2010 | MICROGEN LLC | 101 CHRISTOPHER COLUMBUS BLVD | GALVESTON | TX | 77550 | GALVESTON | USA | R03AI081021 | RAPID FISH DETECTION OF EBV-INFECTED CELLS | 000 | 2 | NIH | 3/18/2010 | $76,725 |
| | 2010 | 2010 | MICROGEN LLC | 101 CHRISTOPHER COLUMBUS BLVD | GALVESTON | TX | 77550 | GALVESTON | USA | R03AI083062 | 3-D ORAL MUCOSA MODEL FOR EBV PATHOGENESIS | 000 | 1 | NIH | 7/6/2010 | $77,500 |
|
| Issue Date FY: 2009 ( Subtotal = $77,500 ) |
| | 2009 | 2009 | MICROGEN LLC | 101 CHRISTOPHER COLUMBUS BLVD | GALVESTON | TX | 77550 | GALVESTON | USA | R03AI081021 | RAPID FISH DETECTION OF EBV-INFECTED CELLS | 000 | 1 | NIH | 3/20/2009 | $77,500 |
|
|
